Literature DB >> 30121810

Simple Vascular Architecture Classification in Predicting Pancreatic Neuroendocrine Tumor Grade and Prognosis.

Ke Chen1,2, Wenming Zhang1,2, Zhaozhen Zhang1,2, Yiping He1,2, Yuan Liu1,2, Xiujiang Yang3,4.   

Abstract

BACKGROUND AND AIM: Vascularity is a critical feature in the evaluation of pancreatic neuroendocrine tumor (PNET). When done by EUS, contrast agents are recommended. However, vascular architecture (VA) can also be evaluated by routine Doppler flow in EUS without contrast agents. Our aim was to provide a simple VA classification in EUS for PNET grade and prognosis.
METHODS: All pathologically proven PNET cases with EUS between 2012 and 2018 were retrospectively analyzed. The Doppler imaging was retrieved for VA classification. Predictive model construction was performed by machine learning algorithms.
RESULTS: A total of 112 PNET cases were evaluated, among which 93 cases were subjected to VA classification. The VA was classified into type A (peritumoral with or without intratumoral vessels [A1 or A2]); type B (only intratumoral vessels); and type C (flow was absent). The VA classification was significantly correlated with tumor grades: 74% type A1 was G1, 73% type B was G2, and 58% type C was G3. Multivariate analysis indicated that elevated serum CA19-9 and type C classification were the independent predictors of G3 tumor. Five machine learning models were constructed, among which random forest was the best one with an AUC of 0.9972. Low-risk patients classified by this model exhibited better prognosis than high-risk patients (p = 0.0087).
CONCLUSIONS: In the novel simple VA classification, peritumoral, intratumoral, and absent vessels are prone to be G1, G2, and G3, respectively. Combined with serum CA19-9 and lesion size, the VA classification could predict tumor grade and prognosis in PNET.

Entities:  

Keywords:  Endosonographic; Pancreatic neuroendocrine tumor; Prognosis; Staging; Tumor grade

Mesh:

Year:  2018        PMID: 30121810     DOI: 10.1007/s10620-018-5240-z

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  22 in total

1.  Clinical outcome and long-term survival of 150 consecutive patients with pancreatic neuroendocrine tumors: A comprehensive analysis by the World Health Organization 2010 grading classification.

Authors:  Ben-Yuan Deng; Fei Liu; Si-Neng Yin; An-Ping Chen; Lin Xu; Bo Li
Journal:  Clin Res Hepatol Gastroenterol       Date:  2018-01-05       Impact factor: 2.947

2.  Efficacy of endoscopic ultrasonography and endoscopic ultrasonography-guided fine-needle aspiration for the diagnosis and grading of pancreatic neuroendocrine tumors.

Authors:  Nao Fujimori; Takashi Osoegawa; Lingaku Lee; Yuichi Tachibana; Akira Aso; Hiroaki Kubo; Ken Kawabe; Hisato Igarashi; Kazuhiko Nakamura; Yoshinao Oda; Tetsuhide Ito
Journal:  Scand J Gastroenterol       Date:  2015-09-11       Impact factor: 2.423

3.  Association between pathologic grade and multiphase computed tomography enhancement in pancreatic neuroendocrine neoplasm.

Authors:  Jinwoo Kang; Ji Kon Ryu; Jun Hyuk Son; Jae Woo Lee; Jin Ho Choi; Sang Hyub Lee; Yong-Tae Kim
Journal:  J Gastroenterol Hepatol       Date:  2018-03-07       Impact factor: 4.029

4.  Pancreatic neuroendocrine carcinomas reveal a closer relationship to ductal adenocarcinomas than to neuroendocrine tumors G3.

Authors:  Björn Konukiewitz; Moritz Jesinghaus; Katja Steiger; Anna Melissa Schlitter; Atsuko Kasajima; Bence Sipos; Giuseppe Zamboni; Wilko Weichert; Nicole Pfarr; Günter Klöppel
Journal:  Hum Pathol       Date:  2018-03-26       Impact factor: 3.466

5.  Contrast harmonic EUS for the prediction of pancreatic neuroendocrine tumor aggressiveness (with videos).

Authors:  Maxime Palazzo; Bertrand Napoléon; Rodica Gincul; Mathieu Pioche; Bertrand Pujol; Christine Lefort; Fabien Fumex; Vincent Hautefeuille; Monique Fabre; Jérome Cros; Michèle Felce; Anne Couvelard; Alain Sauvanet; Philippe Lévy; Philippe Ruszniewski; Laurent Palazzo
Journal:  Gastrointest Endosc       Date:  2018-01-08       Impact factor: 9.427

6.  Preoperative CA 19-9 level is an important prognostic factor in patients with pancreatic adenocarcinoma treated with surgical resection and adjuvant concurrent chemoradiotherapy.

Authors:  Christopher L Hallemeier; Maikel Botros; Michele M Corsini; Michael G Haddock; Leonard L Gunderson; Robert C Miller
Journal:  Am J Clin Oncol       Date:  2011-12       Impact factor: 2.339

Review 7.  Incremental benefit of preoperative EUS for the detection of pancreatic neuroendocrine tumors: a meta-analysis.

Authors:  Paul D James; Apostolos V Tsolakis; Mei Zhang; Paul J Belletrutti; Rachid Mohamed; Derek J Roberts; Steven J Heitman
Journal:  Gastrointest Endosc       Date:  2015-04       Impact factor: 9.427

8.  Pancreatic neuroendocrine neoplasms: Magnetic resonance imaging features according to grade and stage.

Authors:  Riccardo De Robertis; Sara Cingarlini; Paolo Tinazzi Martini; Silvia Ortolani; Giovanni Butturini; Luca Landoni; Paolo Regi; Roberto Girelli; Paola Capelli; Stefano Gobbo; Giampaolo Tortora; Aldo Scarpa; Paolo Pederzoli; Mirko D'Onofrio
Journal:  World J Gastroenterol       Date:  2017-01-14       Impact factor: 5.742

9.  Serum chromogranin A is a useful marker for Japanese patients with pancreatic neuroendocrine tumors.

Authors:  Masayuki Hijioka; Tetsuhide Ito; Hisato Igarashi; Nao Fujimori; Lingaku Lee; Taichi Nakamura; Robert T Jensen; Ryoichi Takayanagi
Journal:  Cancer Sci       Date:  2014-10-18       Impact factor: 6.716

10.  Power Doppler endoscopic ultrasound for the assessment of pancreatic neuroendocrine tumors.

Authors:  Sevastiţa Iordache; Radu Angelescu; Maria Monalisa Filip; Mădălin Ionuţ Costache; Carmen Florina Popescu; Dan-Ionuă Gheonea; Adrian Sãftoiu
Journal:  Endosc Ultrasound       Date:  2012-10       Impact factor: 5.628

View more
  2 in total

Review 1.  Artificial Intelligence and Machine Learning in the Diagnosis and Management of Gastroenteropancreatic Neuroendocrine Neoplasms-A Scoping Review.

Authors:  Athanasios G Pantelis; Panagiota A Panagopoulou; Dimitris P Lapatsanis
Journal:  Diagnostics (Basel)       Date:  2022-03-31

2.  Increased carbohydrate antigen 19-9 expression in a thymic neuroendocrine tumor.

Authors:  Yuki Shimizu; Shintaro Kanda; Toshirou Fukushima; Takashi Kobayashi; Ryoichi Kondo; Tomonobu Koizumi
Journal:  Thorac Cancer       Date:  2021-09-27       Impact factor: 3.500

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.